| Security Name | Ticker | % of Net Assets |
|---|---|---|
| ABBVIE INC | ABBV | 7.56% |
| AMGEN INC. | AMGN | 5.44% |
| GILEAD SCIENCES, INC. | GILD | 4.77% |
| VERTEX PHARMACEUTICALS | VRTX | 4.00% |
| REGENERON PHARMACEUTICALS | REGN | 3.81% |
| INSMED INC | INSM | 2.95% |
| ALNYLAM PHARMACEUTICALS | ALNY | 2.73% |
| NATERA INC | NTRA | 2.43% |
| CORTEVA INC | CTVA | 2.36% |
| EXACT SCIENCES | EXAS | 2.16% |
| ASTRAZENECA PLC ADR | AZN | 2.10% |
| BIOGEN IDEC, INC. | BIIB | 2.04% |
| GUARDANT HEALTH INC | GH | 1.92% |
| ILLUMINA INC | ILMN | 1.80% |
| INCYTE CORP | INCY | 1.73% |
| ROYALTY PHARMA PLC- CL A | RPRX | 1.72% |
| BEONE MEDICINES LTD-ADR | BGNE | 1.72% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 1.66% |
| REVOLUTION MEDICINES INC | RVMD | 1.58% |
| AVIDITY BIOSCIENCES INC | RNA | 1.55% |
| BRIDGEBIO PHARMA INC | BBIO | 1.52% |
| IONIS PHARMACEUTICALS, IN | IONS | 1.45% |
| ARGENX SE - ADR | ARGX | 1.40% |
| NEUROCRINE BIOSCIENCES IN | NBIX | 1.38% |
| VIATRIS INC | VTRS | 1.35% |
| UNITED THERAPEUTICS CORP | UTHR | 1.35% |
| ROIVANT SCIENCES LTD | ROIV | 1.28% |
| EXELIXIS, INC. | EXEL | 1.27% |
| BIOMARIN PHARMACEUTICAL | BMRN | 1.20% |
| CYTOKINETICS INC | CYTK | 1.18% |
| VAXCYTE INC | PCVX | 1.13% |
| ARROWHEAD PHARMACEUTICALS | ARWR | 1.09% |
| HALOZYME THERAPEUTICS INC | HALO | 1.06% |
| PTC THERAPEUTICS | PTCT | 1.05% |
| PROTAGONIST THER | PTGX | 1.04% |
| MODERNA INC | MRNA | 1.04% |
| AXSOME THERAPEUT | AXSM | 1.03% |
| ALKERMES PLC | ALKS | 0.98% |
| NUVALENT INC-A | NUVL | 0.96% |
| BIONTECH SE-ADR | BNTX | 0.91% |
| CRINETICS PHARMACEUTICALS | CRNX | 0.88% |
| CRISPR THERAPEUTICS AG | CRSP | 0.87% |
| VERACYTE INC | VCYT | 0.85% |
| VIKING THERAPEUTICS INC | VKTX | 0.85% |
| AKERO THERAPEUTICS INC | AKRO | 0.83% |
| ADMA BIOLOGICS INC | ADMA | 0.81% |
| DYNE THERAPEUTICS INC | DYN | 0.80% |
| MEDPACE HOLDINGS | MEDP | 0.79% |
| TG THERAPEUTICS | TGTX | 0.79% |
| IDEAYA BIOSCIENCES INC | IDYA | 0.75% |
| LEGEND BIOTECH CORP-ADR | LEGN | 0.75% |
| AMICUS THERAPEUTICS INC | FOLD | 0.72% |
| ULTRAGENYX PHARM | RARE | 0.67% |
| MADRIGAL PHARMAC | MDGL | 0.64% |
| ACADIA PHARMACEUTICALS IN | ACAD | 0.64% |
| DENALI THERAPEUT | DNLI | 0.62% |
| IMMUNOVANT INC | IMVT | 0.57% |
| BEAM THERAPEUTICS INC | BEAM | 0.55% |
| SUMMIT THERAPEUTICS INC | SMMT | 0.52% |
| TWIST BIOSCIENCE CORP | TWST | 0.51% |
| ARCELLX INC | ACLX | 0.51% |
| CELLDEX THERAPEUTICS INC | CLDX | 0.50% |
| APELLIS PHARMACE | APLS | 0.50% |
| SAREPTA THERAPEU | SRPT | 0.50% |
| ASCENDIS PHA-ADR | ASND | 0.49% |
| KRYSTAL BIOTECH INC | KRYS | 0.47% |
| DYNAVAX TECHNOLOGY | DVAX | 0.47% |
| RECURSION PHARMACEUTICALS | RXRX | 0.46% |
| AGIOS PHARMACEUT | AGIO | 0.35% |
| NOVAVAX INC | NVAX | 0.33% |
| SOLENO THERAPEUTICS INC | SLNO | 0.31% |
| INTELLIA THERAPE | NTLA | 0.30% |
| IOVANCE BIOTHERAPEUTICS | IOVA | 0.20% |
| Other (Cash, derivatives and other liabilities) | 0.50% | |
| Total: | ||
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.